Maravai Lifesciences Holdings (MRVI) Return on Capital Employed (2021 - 2026)

Maravai Lifesciences Holdings' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 24.06% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 482.0% year-over-year to 24.06% in Q1 2026; TTM through Mar 2026 was 24.06%, a 482.0% increase from a year earlier, with the FY2025 full-year figure at 25.49%, down 571.0% from the prior year.
• Return on Capital Employed improved to 24.06% in Q1 2026 per MRVI's latest filing, from 28.14% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 33.3% in Q1 2022 and bottomed at 37.12% in Q2 2025.
• The 5-year median for Return on Capital Employed is 3.77% (2024), against an average of 2.01%.
• Across the five-year window, Return on Capital Employed jumped 1792 bps in 2022 and sank 3313 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 26.64% in 2022, then slumped by 107 bps to 1.77% in 2023, then slumped by 1127 bps to 21.69% in 2024, then slipped by 30 bps to 28.14% in 2025, then climbed by 14 bps to 24.06% in 2026.
• Per Business Quant, the three latest MRVI Return on Capital Employed figures stand at 24.06% (Q1 2026), 28.14% (Q4 2025), and 23.93% (Q3 2025).